****

**National Cancer Recovery Group**

**National Cancer Quality Steering Group**

**Oesophago-Gastric Cancer**

**Clinical Quality Performance Indicators**

**Engagement Document**

**January 2023**

**Contents Page**

[1. National Cancer Quality Programme 3](#_Toc121925470)

[1.1 Quality Assurance and Continuous Quality Improvement 3](#_Toc121925471)

[2. Quality Performance Indicator Development Process 3](#_Toc121925472)

[3. QPI Formal Review Process 4](#_Toc121925473)

[4. Format of the Quality Performance Indicators 4](#_Toc121925474)

[5. Supporting Documentation 5](#_Toc121925475)

[6. Quality Performance Indicators for Upper GI Cancer 6](#_Toc121925476)

[QPI 1 - Endoscopy 6](#_Toc121925477)

[QPI 3 - Multi-Disciplinary Team (MDT) Meeting 7](#_Toc121925478)

[QPI 4 - Staging and Treatment Intent 8](#_Toc121925479)

[QPI 5 - Nutritional Assessment 10](#_Toc121925480)

[QPI 6 - Appropriate Selection of Surgical Patients 12](#_Toc121925481)

[QPI 7 - 30/90 Day Mortality Following Surgery 13](#_Toc121925482)

[QPI 8 - Lymph Node Yield 14](#_Toc121925483)

[QPI 9 - Length of Hospital Stay Following Surgery 15](#_Toc121925484)

[QPI 10 - Resection Margins 16](#_Toc121925485)

[QPI 12 - 30 Day Mortality Following SACT Treatment 18](#_Toc121925486)

[QPI 13 - HER2 Status for Decision Making 19](#_Toc121925487)

[QPI 14 - Clinical Trial and Research Study Access 20](#_Toc121925488)

[QPI 15 – PD-L1 Status for Decision Making 21](#_Toc121925489)

[7. Survival 22](#_Toc121925490)

[8. Areas for Future Consideration 22](#_Toc121925491)

[9. Governance and Scrutiny 22](#_Toc121925492)

[9.1 National 22](#_Toc121925493)

[9.2 Regional – Regional Cancer Networks 23](#_Toc121925494)

[9.3 Local – NHS Boards 23](#_Toc121925495)

[10. How to participate in the engagement process 23](#_Toc121925496)

[10.1 Submitting your comments 23](#_Toc121925497)

[10.2 Engagement feedback 24](#_Toc121925498)

[11. References 25](#_Toc121925499)

[12. Appendices 27](#_Toc121925500)

[Appendix 1: QPI Development Process 27](#_Toc121925501)

[Appendix 2: Upper GI Cancer QPI Formal Reviews 30](#_Toc121925502)

[Appendix 3: 3 Yearly National Governance Process and Improvement Framework for Cancer Care 32](#_Toc121925503)

[Appendix 4: Regional Annual Governance Process and Improvement Framework for Cancer Care 33](#_Toc121925504)

[Appendix 5: Glossary of Terms 34](#_Toc121925505)

# 1. National Cancer Quality Programme

Beating Cancer: Ambition and Action (2016)1 details a commitment to delivering the National Cancer Quality Programme across NHSScotland, with a recognised need for national cancer QPIs to support a culture of continuous quality improvement. Addressing variation in the quality of cancer services is pivotal to delivering improvements in quality of care. This is best achieved if there is consensus and clear indicators for what good cancer care looks like.

Small sets of cancer specific outcome focussed, evidence based indicators are in place for 19 different tumour types. These QPIs ensure that activity is focused on those areas that are most important in terms of improving survival and individual care experience whilst reducing variation and supporting the most effective and efficient delivery of care for people with cancer. QPIs are kept under regular review and are responsive to changes in clinical practice and emerging evidence.

A programme to review and update the QPIs in line with evolving evidence is in place as well as robust mechanism by which additional QPIs will be developed over the coming years.

## 1.1 Quality Assurance and Continuous Quality Improvement

The ultimate aim of the programme is to develop a framework, and foster a culture of continuous quality improvement, whereby real time data is reviewed regularly at an individual Multi Disciplinary Team (MDT)/Unit level and findings actioned to deliver continual improvements in the quality of cancer care. This is underpinned and supported by a programme of regional and national comparative reporting and review.

NHS Boards are required to report against QPIs as part of a mandatory, publicly reported, programme at a national level. A rolling programme of reporting is in place, with approximately three national tumour specific summary reports published annually. These reports highlight the publication of performance data in the Cancer QPI Dashboard held within the Scottish Cancer Registry and Intelligence Service (SCRIS). The dashboard includes comparative reporting of performance against QPIs at MDT/Unit level across NHSScotland, trend analysis and survival. This approach helps overcome existing issues relating to the reporting of small volumes in any one year.

In the intervening years tumour specific QPIs will be monitored on an annual basis through established Regional Cancer Network and local governance processes, with analysed data submitted to Public Health Scotland (PHS) for inclusion in the Cancer QPI Dashboard and subsequent national summary reports. This ensures that timely action is taken in response to any issues that may be identified through comparative reporting and systematic review.

# 2. Quality Performance Indicator Development Process

The QPI development process was designed to ensure that indicators are developed in an open, transparent and timely way.

The Upper GI Cancer QPI Development Group was convened in June 2011, chaired by Dr Jennifer Armstrong (Senior Medical Officer, Scottish Government). Membership of this group included clinical representatives drawn from the three regional cancer networks, Healthcare Improvement Scotland, Information Services Division (ISD) and patient/carer representatives.

The development process and membership of the development group can be found in appendix 1.

# 3. QPI Formal Review Process

As part of the National Cancer Quality Programme a systematic rolling programme of national review process has been developed. This ensures all tumour specific QPIs are subject to formal review following every 3rd year of comparative QPI data analysis.

The formal review process is clinically driven with proposals for change sought from specialty specific representatives in each of the Regional Cancer Networks. It is designed to be flexible in terms of the extent of review required with tumour specific Regional Clinical Leads undertaking a key role in this decision making. Formal review meetings to further discuss proposals are arranged where deemed necessary. The review builds on existing evidence using expert clinical opinion to identify where new evidence is available, and a full public engagement exercise will take place where significant revisions have been made or new QPIs developed.

During formal review QPIs may be archived and replaced with new QPIs. Triggers for doing so include significant change to clinical practice, targets being consistently met by all Boards and publication of new evidence. Where QPIs have been archived, associated data items will continue to be collected where these are utilised for other indicators, or measures such as survival analysis.

Any new QPIs are developed in line with the following criteria:

* **Overall importance** – does the indicator address an area of clinical importance that would significantly impact on the quality and outcome of care delivered?
* **Evidence based** – is the indicator based on high quality clinical evidence?
* **Measurability** – is the indicator measurable i.e. are there explicit requirements for data measurement and are the required data items accessible and available for collection?

Three formal reviews of the Upper GI Cancer QPIs have been undertaken to date. Further information can be found in appendix 2.

# 4. Format of the Quality Performance Indicators

QPIs are designed to be clear and measurable, based on sound clinical evidence whilst also taking into account other recognised standards and guidelines.

* Each QPI has a **short title** which will be utilised in reports as well as a fuller **description** which explains exactly what the indicator is measuring.
* This is followed by a brief overview of the **evidence base and rationale** which explains why the development of this indicator was important.
* The measurability **specifications** are then detailed; these highlight how the indicator will actually be measured in practice to allow for comparison across NHSScotland.
* Finally a **target** is indicated, which dictates the level each unit should be aiming to achieve against each indicator.

In order to ensure that the chosen target levels are the most appropriate and drive continuous quality improvement as intended they will be kept under review and revised as necessary, if further evidence or data becomes available.

Rather than utilising multiple exclusions, a tolerance level has been built into the QPIs. It is very difficult to accurately measure patient choice, co-morbidities and patient fitness therefore target levels have been set to account for these factors. Further detail is noted within QPIs where there are other factors which influenced the target level.

Where ‘less than’ (<) target levels have been set the rationale has been detailed within the relevant QPI. All other target levels should be interpreted as ‘greater than’ (>) levels.

# 5. Supporting Documentation

A national minimum core dataset and a measurability specification have been developed in parallel with the indicators to support the monitoring and reporting of Upper GI Cancer QPIs. The latest version of these documents can be found at:

[Public Health Scotland Cancer Audit](https://www.isdscotland.org/Health-Topics/Cancer/Cancer-Audit/)

# 6. Quality Performance Indicators for Upper GI Cancer

## QPI 1 - Endoscopy

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Patients with oesophageal or gastric cancer should undergo endoscopy and biopsy to reach a diagnosis of cancer. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who have a histological diagnosis made within 6 weeks of initial endoscopy and biopsy. | |
| **Rationale and Evidence:** | For diagnosis of oesophageal or gastric cancer the use of endoscopy is recommended2.  A tissue diagnosis in cases of suspected oesophageal and gastric cancer requires adequate sampling of the suspicious lesion. Multiple biopsies should be obtained and the number of biopsies examined should always be reported 2.  This QPI utilises a 6 week timeframe from initial endoscopy and biopsy to histological diagnosis. This has been deemed appropriate by the QPI Review Group to account for clinical situations where the suspicion of malignancy is high however the initial biopsy result is negative. It also accounts for those patients where biopsy has not been possible at the initial endoscopy procedure due to reasons such as anticoagulant use or gastric outlet obstruction. This ensures there are no delays in undergoing a repeat investigation if required and thus avoiding the possibility of presenting with a more advanced cancer. | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric cancer who undergo endoscopy who have a histological diagnosis made within 6 weeks of initial endoscopy and biopsy[[1]](#footnote-1). |
| **Denominator:** | All patients with oesophageal or gastric cancer who undergo endoscopy. |
| **Exclusions:** | * No exclusions |
| **Target:** | 95%  The tolerance within this target is designed to account for factors of patient choice. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 3 - Multi-Disciplinary Team (MDT) Meeting

|  |  |  |  |
| --- | --- | --- | --- |
| **QPI Title:** | Patients should be discussed by a multidisciplinary team prior to definitive treatment. | | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who are discussed at MDT meeting before definitive treatment. | | |
| **Rationale and Evidence:** | Evidence suggests that patients with cancer managed by a multi-disciplinary team have a better outcome. There is also evidence that the multidisciplinary management of patients increases their overall satisfaction with their care3.  Discussion prior to definitive treatment decisions being made provides reassurance that patients are being managed appropriately. | | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric cancer discussed at the MDT before definitive treatment. | |
| **Denominator:** | All patients with oesophageal or gastric cancer. | |
| **Exclusions:** | | * Patients who died before first treatment. |
| **Target:** | 95%  The tolerance within this target accounts for situations where patients require treatment urgently. | | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 4 - Staging and Treatment Intent

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Patients with oesophageal or gastric cancer should be staged using the TNM[[2]](#footnote-2) staging system and have statement of treatment intent recorded prior to treatment commencing. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who have TNM stage and treatment intent recorded at MDT meeting prior to treatment.  **Please note:** The specifications of this QPI are separated to ensure clear measurement of patients who have the following recorded at MDT meeting prior to treatment:   1. TNM stage; and 2. Treatment Intent. | |
| **Rationale and Evidence:** | It is important to discuss and consider treatment intent as patients with incurable disease treated as radical will be poorly served.  Patients with gastric or oesophageal cancer should undergo careful staging to assess the extent of disease and inform treatment decision making2. This may involve multiple investigations.  Clinical staging should follow the principles of TNM classification4; this aids the determination of prognosis and choice of therapy. A statement regarding clinical stage and treatment intent should be recorded at the MDT.  For patients presenting with metastatic disease it is not always possible or appropriate to determine T and N stage. Within the QPI TxNxM1[[3]](#footnote-3) is therefore accepted as complete staging in this situation. | |
| **Specification (i):** | **Numerator:** | Number of patients with oesophageal or gastric cancer who have TNM stage recorded at MDT meeting prior to treatment. |
| **Denominator:** | All patients with oesophageal or gastric cancer. |
| **Exclusions:** | * No exclusions |
| **Target:** | 90%  The tolerance within this target accounts for situations where patients are not fit enough to undergo investigations and/or treatment; however, in these cases an attempt at TNM staging should be undertaken based on the information available. It also accounts for those patients who die before MDT meeting. | |

(Continued overleaf…)

**QPI 4 - Staging and Treatment Intent (continued....)**

|  |  |  |
| --- | --- | --- |
| **Specification (ii):** | **Numerator:** | Number of patients with oesophageal or gastric cancer who have treatment intent recorded at MDT meeting prior to treatment. |
| **Denominator:** | All patients with oesophageal or gastric cancer. |
| **Exclusions:** | * No exclusions |
| **Target:** | 95%  The tolerance within this target accounts for those patients who die before MDT meeting. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | * ***No change to QPI – data definition changes to account for patients who are diagnosed and undergo definitive treatment at the time of EMR (allowing TNM to be documented at MDT post EMR).*** * ***In addition, to add a note stating that the ‘Treatment Intent Recorded at MDT’ should be the final one prior to treatment in order to account for amendments following discussion with the patient.*** |

## QPI 5 - Nutritional Assessment

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Patients with oesophageal or gastric cancer should be appropriately assessed by a dietitian to optimise nutritional status. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who undergo nutritional screening before first treatment and are assessed by a dietitian where appropriate.  **Please note:** The specifications of this QPI have been separated to ensure clear measurement of patients who:   1. Undergo nutritional screening with the Malnutrition Universal Screening Tool (MUST) before first treatment; and 2. Are at high risk of malnutrition (MUST Score of 2 or more) and are assessed by a dietitian. | |
| **Rationale and Evidence:** | All patients with oesophageal or gastric cancer should be screened using a validated nutritional screening tool to assess nutritional risk. Those at risk of nutritional problems should have access to a registered dietitian to provide appropriate advice2.  Poor nutritional status is a risk factor for poor tolerance of treatment whether curative or palliative and can impact greatly on quality of life5,6.  Patients who are suitable for radical treatment, e.g. surgery, and who are malnourished, benefit from nutrition support prior to treatment. In addition, all patients who undergo surgery benefit from early post-operative nutrition. Both can reduce complications such as sepsis, poor wound healing and reduce length of stay7.  To ensure focussed measurement, this QPI examines patients with a MUST score of 2 or more. Although this ensures those patients most at risk of malnutrition are being targeted for dietetic assessment, it is important that all patients, regardless of score, are managed appropriately for nutritional care. Although the MUST score should be applied for the purposes of this QPI, it is acknowledged that there are also other tools available which may be used for nutritional assessment. | |
| **Specification (i):** | **Numerator:** | Number of patients with oesophageal or gastric cancer who undergo nutritional screening with the MUST before first treatment. |
| **Denominator:** | All patients with oesophageal or gastric cancer. |
| **Exclusions:** | * No exclusions. |
| **Target:** | 95%  The tolerance within this target accounts for those patients with very advanced disease who may not be fit for treatment, and for factors of patient choice. | |

(Continued overleaf…)

**QPI 5 - Nutritional Assessment (continued….)**

|  |  |  |
| --- | --- | --- |
| **Specification (ii):** | **Numerator:** | Number of patients with oesophageal or gastric cancer at high risk of malnutrition (MUST score of 2 or more) who are assessed by a dietitian. |
| **Denominator:** | All patients with oesophageal or gastric cancer at high risk of malnutrition (MUST score of 2 or more). |
| **Exclusions:** | * No exclusions. |
| **Target:** | 90%  The tolerance within this target accounts for those patients with very advanced disease in whom dietetics assessment may not be appropriate, as well as factors of patient choice. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 6 - Appropriate Selection of Surgical Patients

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Patients with oesophageal or gastric cancer whose treatment plan is neoadjuvant chemotherapy or chemoradiotherapy followed by surgery should progress to surgery following completion of this treatment. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who receive neo-adjuvant chemotherapy or chemoradiotherapy who then go on to have surgical resection. | |
| **Rationale and Evidence:** | Patients with oesophageal or gastric cancer who are suitable for surgical resection should be offered neoadjuvant chemotherapy treatment2,8,9. Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery provides a survival benefit for patients with oesophageal or gastric cancer10,11.  It is optimal management that patients who undergo neoadjuvant chemotherapy or chemoradiotherapy proceed to resectional (curative) surgery; various reasons may affect this including initial under-staging of disease. | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric cancer who receive neo-adjuvant chemotherapy or chemoradiotherapy who then undergo surgical resection. |
| **Denominator:** | All patients with oesophageal or gastric cancer who receive neo-adjuvant chemotherapy or chemoradiotherapy. |
| **Exclusions:** | * No exclusions |
| **Target:** | 80%  The tolerance within this target accounts for the fact that some patients’ disease may progress despite neo-adjuvant chemotherapy or chemoradiotherapy, and for factors of patient choice. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 7 - 30/90 Day Mortality Following Surgery

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | 30 and 90 day mortality following surgical resection for oesophageal or gastric cancer. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who die within 30 or 90 days of surgical resection for oesophageal or gastric cancer. | |
| **Rationale and Evidence:** | Treatment related mortality is a marker of the quality and safety of the whole service provided by the Multi Disciplinary Team (MDT)12.  Treatment should only be undertaken in individuals that may benefit from treatment, that is, disease specific treatments should not be undertaken in futile situations. This QPI is intended to ensure treatment is given appropriately. | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric cancer who undergo surgical resection who die within 30/90 days of treatment. |
| **Denominator:** | All patients with oesophageal or gastric cancer who undergo surgical resection. |
| **Exclusions:** | * No exclusions |
| **Target:** | 30 day - <5%  90 day - <7.5% | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 8 - Lymph Node Yield

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | For patients with oesophageal or gastric cancer undergoing curative resection the number of lymph nodes examined should be maximised. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who undergo surgical resection where ≥15 lymph nodes are resected and pathologically examined. | |
| **Rationale and Evidence:** | Maximising the number of lymph nodes resected and analysed enables reliable staging which influences treatment decision making.  Evidence recommends that at least 15 lymph nodes are resected and examined by a pathologist9,13. | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric cancer who undergo surgical resection where ≥15 lymph nodes are resected and pathologically examined. |
| **Denominator:** | All patients with oesophageal or gastric cancer who undergo surgical resection. |
| **Exclusions:** | * No exclusions |
| **Target:** | Gastric cancer - 80%  Oesophageal cancer – 90%  The tolerance within this target accounts for situations where patients are not fit enough to undergo extensive lymphadenectomy and for situations where surgical resection is performed for palliation. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 9 - Length of Hospital Stay Following Surgery

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Length of hospital stay following surgery for oesophageal or gastric cancer should be as short as possible. | |
| **Description:** | Proportion of patients undergoing surgical resection for oesophageal or gastric cancer who are discharged within 14 days of surgical procedure. | |
| **Rationale and Evidence:** | Length of hospital stay acts as a surrogate measure for the quality of surgery and post-operative care for patients undergoing surgical resection for oesophagogastric cancer.  This QPI is intended as a surrogate marker to address various issues of quality care including surgery, post-operative complications and access to community services. | |
| **Specifications:** | **Numerator:** | Number of patients undergoing surgical resection for oesophageal or gastric cancer who are discharged within 14 days of surgical procedure. |
| **Denominator:** | All patients undergoing surgical resection for oesophageal or gastric cancer. |
| **Exclusions** | * No exclusions |
| **Target:** | 60%  The tolerance within this target is designed to account for situations where it is not safe or practical for patients to go home within 14 days of surgery. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***No Change to QPI*** |

## QPI 10 - Resection Margins

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Oesophageal and gastric cancers which are surgically resected should be adequately excised. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who undergo surgical resection in which surgical margin is clear of tumour, i.e. negative surgical margin.  **Please note**: The specifications of this QPI have been separated to ensure clear measurement of both:   1. Oesophageal cancer patients who have a clear circumferential margin; and 2. Oesophageal and gastric cancer patients who have a clear longitudinal margin. | |
| **Rationale and Evidence:** | Tumour involvement of surgical resection margins is a negative prognostic factor; therefore surgery should aim to ensure resection margins are clear of tumour.  Oesophageal and gastric cancer resectional surgery should aim to ensure complete excision of the tumour, i.e. achieve an R0 resection, as this affects prognosis and long term patient outcome2,9. | |
| **Specification (i):** | **Numerator:** | Number of patients with oesophageal cancer who undergo surgical resection in which circumferential surgical margin is clear of tumour. |
| **Denominator:** | All patients with oesophageal cancer who undergo surgical resection. |
| **Exclusions:** | * No exclusions. |
| **Target:** | 75% | |
| **Specification (ii):** | **Numerator:** | Number of patients with oesophageal or gastric cancer who undergo surgical resection in which longitudinal surgical margin is clear of tumour. |
| **Denominator:** | All patients with oesophageal or gastric cancer who undergo surgical resection. |
| **Exclusions:** | * No exclusions. |
| **Target:** | 95% | |

|  |  |
| --- | --- |
| ***Revision(s):*** | * ***Specification (i) – target increased from 70% to 75% for circumferential surgical margin that is clear of tumour. This is comparable with NHS England.*** |

**QPI 11 - Curative Treatment Rates**

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | Patients with oesophageal or gastric cancer should undergo curative treatment whenever possible. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer who undergo curative treatment, this includes:   * Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery; * Primary surgery; * Radical chemoradiotherapy; * Radical radiotherapy; and * Endoscopic Mucosal Resection. | |
| **Rationale and Evidence:** | Curative treatment should be offered to as many patients as possible, as this is proven to have a survival benefit. The UK National Oseophago-Gastric Cancer Audit Report (2016) data demonstrate that around three-quarters of patients receiving treatment with curative intent survived at least 1 year from diagnosis. At two years, just over one-half of patients were still alive14.  Surgical resection of the tumour remains the mainstay of curative treatment for patients with oesophageal or gastric cancer14.  Chemoradiotherapy should be considered in patients with oesophageal cancer who have locally advanced disease, those unfit for surgery or those who decline surgery2.  In the older population where patients may be unfit for radical chemoradiotherapy, radiotherapy alone can have comparable survival and should be considered as an acceptable alternative for oesophageal squamous cell carcinoma15. | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric cancer who undergo curative treatment. |
| **Denominator:** | All patients with oesophageal or gastric cancer. |
| **Exclusions:** | * No exclusions |
| **Target:** | 35%  The tolerance within this target takes into consideration patient choice, fitness and co-morbidities which preclude curative treatment.  It is intended as a composite measure of the entire diagnostic and staging pathway, but recognises that the majority of patients will have advanced disease at presentation. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | ***Added in radical radiotherapy as a curative treatment (oesophageal squamous cell carcinoma).***  ***Rationale and evidence updated.*** |

## QPI 12 - 30 Day Mortality Following SACT Treatment

|  |  |
| --- | --- |
| ***Revision(s):*** | * ***QPI Removed***   ***SACT Mortality for all tumour types will be measured separately from the QPI process using data from CEPAS (Chemotherapy Electronic Prescribing and Administration System). This will allow all patients to be captured rather than just newly diagnosed patients within the audit.*** |

## 

## QPI 13 - HER2 Status for Decision Making

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | HER2 status should be available to inform treatment decision making in patients with oesophageal or gastric adenocarcinoma. | |
| **Description:** | Proportion of patients with oesophageal or gastric adenocarcinoma undergoing first line palliative chemotherapy as their initial treatment for whom the HER2 status is reported prior to commencing treatment. | |
| **Rationale and Evidence:** | HER2 is a negative prognostic factor, demonstrating an impact on recurrence in HER2-positive tumours and therefore having a significant influence on treatment decisions16.  Trastuzumab in combination with doublet chemotherapy is recommended for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease17,18.  It is important to ensure the availability of HER2 status to inform treatment decision making. Delay in the availability of a HER2result may lead to a delay in appropriate therapy and make communication of a clear plan to the patient more difficult. | |
| **Specifications:** | **Numerator:** | Number of patients with oesophageal or gastric adenocarcinoma undergoing first line palliative chemotherapy as their initial treatment for whom the HER2 status is reported prior to commencing treatment. |
| **Denominator:** | All patients with oesophageal or gastric adenocarcinoma undergoing first line palliative chemotherapy as their initial treatment. |
| **Exclusions** | * None. |
| **Target:** | 90%  The tolerance within this target is designed to account for situations where there is insufficient tissue for analysis, and for patients with co-morbidities for whom targeted HER2 therapy would not be appropriate. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | * **No change to QPI.** |

## QPI 14 - Clinical Trial and Research Study Access

|  |  |
| --- | --- |
| ***Revision(s):*** | * ***QPI Removed***   ***This QPI is now being removed from the individual tumour specific QPI documents and will be replaced by a suite of measures reported via the NHS Research Scotland Central Management Team*** |

## QPI 15 – PD-L1 Status for Decision Making

|  |  |  |
| --- | --- | --- |
| **QPI Title:** | PD-L1 status should be available to inform treatment decision making in patients with oesophageal or gastric cancer. | |
| **Description:** | Proportion of patients with oesophageal or gastric cancer undergoing first line palliative chemotherapy as their initial treatment for whom the PD-L1 status is reported prior to commencing treatment.  **Please note:** The specifications of this QPI have been separated to ensure clear measurement of the following:   1. Patients with oesophageal or gastric adenocarcinoma undergoing first line palliative chemotherapy as their initial treatment; and 2. Patients with oesophageal squamous cell carcinoma undergoing palliative chemotherapy as their initial treatment. | |
| **Rationale and Evidence:** | PD-L1 is an important prognostic indicator for patients with oesophageal cancer19. Tumours which demonstrate PD-L1 expression can respond to immunotherapy treatments e.g. Pembrolizumab.  Pembrolizumab in combination with chemotherapy was associated with significantly improved progression-free survival and overall survival compared with chemotherapy alone20.  It is important to ensure the availability of PD-L1 status to inform treatment decision making. Delay in the availability of a PD-L1 result may lead to a delay in appropriate therapy and make communication of a clear plan to the patient more difficult. | |
| **Specification (i):** | **Numerator:** | Number of patients with oesophageal or gastric adenocarcinoma undergoing first line palliative chemotherapy as their initial treatment for whom the PD-L1 status is reported prior to commencing treatment. |
| **Denominator:** | All patients with oesophageal or gastric adenocarcinoma undergoing first line palliative chemotherapy as their initial treatment |
| **Exclusions** | None. |
| **Specification (ii):** | **Numerator:** | Number of patients with oesophageal squamous cell carcinoma undergoing first line palliative chemotherapy as their initial treatment for whom the PD-L1 status is reported prior to commencing treatment. |
| **Denominator:** | All patients with oesophageal squamous cell carcinoma undergoing first line palliative chemotherapy as their initial treatment. |
| **Exclusions** | None. |
| **Target:** | 1. 90%   The tolerance level within this target is designed to account for situations where there is insufficient tissue for analysis, or for patients with co-morbidities for whom targeted PD-L1 therapy would not be appropriate. | |

|  |  |
| --- | --- |
| ***Revision(s):*** | * ***NEW QPI*** |

# 7. Survival

Improving survival forms an integral part of the National Cancer Quality Programme. Upper GI cancer survival analysis will be reported and analysed on a 3 yearly basis by Public Health Scotland (PHS). The specific issues which will be addressed will be identified by an expert group ahead of any analysis being undertaken, as per the agreed national cancer quality governance and improvement framework.

The Upper GI Cancer QPI Group has identified, during the QPI development process, the following issues for survival analysis:

* Overall 1, 2 and 5 year survival.

To ensure consistent application of survival analysis, it has been agreed that a single analyst on behalf of all three regional cancer networks undertakes this work. Survival analysis will be scheduled as per the national survival analysis and reporting timetable, agreed with the National Cancer Quality Steering Group and National Cancer Recovery Group. This reflects the requirement for record linkage and the more technical requirements of survival analyses which makes it difficult for individual Boards to undertake routinely and in a nationally consistent manner.

# 8. Areas for Future Consideration

The Upper GI Cancer QPI Groups have not been able to identify sufficient evidence, or determine appropriate measurability specification, to address all areas felt to be of key importance in the treatment of upper GI cancer, and therefore in improving the quality of care for patients affected by upper GI cancer.

The following areas for future consideration have been raised across the lifetime of the Upper GI Cancer QPIs.

* Palliative treatment rates.
* Levels of early stage disease.
* Treatment of early stage disease.
* Surgical volumes.
* Quality of post operative care and recovery following surgery.
* Endoscopic Mucosal Resection.

# 9. Governance and Scrutiny

A national and regional governance framework to assure the quality of cancer services in NHSScotland has been developed; key roles and responsibilities within this are set out below. Appendices 4 and 5 provide an overview of these governance arrangements diagrammatically. The importance of ensuring robust local governance processes are in place is recognised and it is essential that NHS Boards ensure that cancer clinical audit is fully embedded within established processes.

## 9.1 National

* National Cancer Recovery Group
  + - Accountable for overall National Cancer Quality Programme and overseeing the quality of cancer care across NHSScotland.
* Healthcare Improvement Scotland
  + - Proportionate scrutiny of performance.
    - Support performance improvement.
    - Quality assurance: ensure robust action plans are in place and being progressed via regions/Boards to address any issues identified.
* Public Health Scotland (PHS)

Publish national comparative report on tumour specific QPIs and survival for three tumour types per annum and specified generic QPIs as part of the rolling programme of reporting.

## 9.2 Regional – Regional Cancer Networks

* Annual regional comparative analysis and reporting against tumour specific QPIs.
* Support national comparative reporting of specified generic QPIs.
* Identify and share good practice.
* In conjunction with constituent NHS Boards identify regional and local actions required to develop an action plan to address regional issues identified.
* Review and monitor progress against agreed actions.
* Performance review and monitoring of progress against agreed actions.
* Provide assurance to Board Chief Executive Officers and National Cancer Recovery Group that any issues identified have been adequately and timeously progressed.

## 9.3 Local – NHS Boards

* Collect and submit data for regional comparative analysis and reporting in line with agreed measurability and reporting schedule (generic and tumour specific QPIs).
* Utilise local governance structures to review performance, develop local action plans and monitor delivery.
* Demonstrate continual improvements in quality of care through on-going review, analysis and feedback of clinical audit data at an individual multidisciplinary team (MDT) or unit level.

# 10. How to participate in the engagement process

In order to ensure wide inclusiveness of clinical and management colleagues from across NHSScotland, patients affected by oesophageal and gastric cancer and the wider public, draft documentation will be widely circulated for comment and feedback. This will include professional groups, health service staff, voluntary organisations and other relevant individuals.

## 10.1 Submitting your comments

Forms for submission of comments on the Oesophago-Gastric Upper GI cancer QPIs are available from the Scottish Government Consultation Hub (website details below):

<https://consult.scotland.gov.uk/>

If you require any further information regarding the engagement process please use the email address below.

**Email:** [UGIQPIPublicEngagement@gov.scot](mailto:UGIQPIPublicEngagement@gov.scot)

## 10.2 Engagement feedback

At the end of the engagement period, all comments and responses will be collated for review by the Upper GI Cancer QPI Formal Review Group. Those who have participated in the engagement process will receive an overview of the changes made and a copy of the final Upper GI Cancer QPI document.

# 11. References

1. Scottish Government (2016). Beating Cancer: Ambition and Action Available from: <http://www.gov.scot/Resource/0049/00496709.pdf>.
2. SIGN (2006). Management of oesophageal and gastric cancer. (accessed August 2013).
3. NHS Quality Improvement Scotland (2008). Management of Core Cancer Services Standards [online]. (accessed August 2013).
4. Royal College of Pathologists (2007). Dataset for the histopathological reporting of gastric carcinoma (2nd edition) [online]. Available from: <https://www.rcpath.org/uploads/assets/d424aaee-6170-4171-ba184326229af027/Dataset-for-the-histopathological-reporting-of-gastric-carcinoma.pdf> (accessed August 2013).
5. Chen DW, Wei Fei Z, Zhang YC, et al. (2007). Perioperative enteral nutrition and quality of life of severely malnourished. Eur J Clin Nutr.   
   61(2), 200-204.
6. Bozetti F, Cozzaglio L, Gavazzi C, et al (1998). Nutrition support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy and survival. Tumori. 84(6), 681-6.
7. Arendsa J, Bodokyb G, Bozzettic F, et al (2006). ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clinical Nutrition. 25, 245–259.
8. Knight G, Earle CC, Cosby R, Coburn N, Yuussef Y, Spithiff K, et al. (2011). Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer [online]. Available from: (Accessed August 2013).
9. Allum WH, Blazeby JM, Griffin SM, et al. on behalf of: Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (2011) Guidelines for the Management of Oesophageal and Gastric Cancer. Gut. 60, 1449-1472 [online]. (accessed August 2013).
10. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226e34.
11. Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol 2015; 6:534–543.
12. NHS Quality Improvement Scotland (2008). Clinical Standards for the Management of Bowel Cancer [online]. (accessed August 2013).
13. Association of Comprehensive Cancer Centres (2009). Gastric Carcinoma [online]. Available:<http://www.oncoline.nl/index.php?pagina=/richtlijn/item/pagina.php&richtlijn_id=740>. (accessed August 2013).
14. National Oesophago-Gastric Cancer Audit (2016) An audit of the care received by people with Oesophago-Gastric Cancer in England and Wales 2016 Annual Report [online]. Available from: <http://content.digital.nhs.uk/catalogue/PUB21561/clin-audi-supp-prog-oeso-gast-2016-rep.pdf> (accessed February 2017).
15. Derby S, Forshaw M, Lowrie C et al. Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the oesophagus. BMJ Open Gastroenterology 2021; 8:e000492. doi 10.1136/bmjgast-2020-000492.
16. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol 2016; 22:4619-25.
17. [Bang YJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bang%20YJ%5BAuthor%5D&cauthor=true&cauthor_uid=20728210) et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 28;376(9742):687-97
18. Scottish Medicines Consortium (2015). Trastuzumab SMC 623/10 [online]. Available from:<https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-herceptin-resubmission-62310/> (accessed February 2017)
19. Dhakras P, Uboha N, Horner V, Reinig E, Matkowskyj KA. (2020) Gastrointestinal cancers: current biomarkers in oesophageal and gastric adenocarcinoma. Transl Gastroenterol Hepatol 2020;5;55.doi: 10.21037/tgh.2020.01.08. Available from:<https://tgh.amegroups.com/article/view/5762/html#:~:text=MSI%20testing%20by%20polymerase%20chain,more%20of%20the%20MMR%20proteins.>

(accessed December 2022)

1. Scottish Medicines Consortium (2022). Pembrolizumab SMC 2420 [online]. Available from:<https://www.scottishmedicines.org.uk/media/6848/de-pembrolizumab-keytruda-smc2420.pdf> (accessed November 2022)
2. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J.182(18), E839-E842 [online]. Available from:

<http://www.cmaj.ca/content/182/18/E839.full.pdf+html?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=brouwers&searchid=1&FIRSTINDEX=0&volume=182&issue=18&resourcetype=HWCIT%2520%2520%2520> (accessed August 2013)

# 12. Appendices

## Appendix 1: QPI Development Process

***Preparatory Work and Scoping***

The preparatory work involved the development of a structured briefing paper by Healthcare Improvement Scotland. This paper took account of existing, high quality, clinical guidance and provided a basis for the development of QPIs.

The scope for development of Upper GI cancer QPIs and a search narrative were defined and agreed by the Upper GI Cancer QPI Development Group. The table below shows the final criteria used in the literature search.

|  |  |
| --- | --- |
| Inclusion | Exclusion |
| *Topics* (population/patient): Oesophageal (esophageal), gastric  *Topics* (intervention): Diagnosis, staging, surgery, non-surgical management, treatment, palliative chemotherapy, radiotherapy and surgery. | *Topics:* Communication/information, end of life care, pain management, prevention, screening and secondary liver cancer. |
| Adults only |  |
| *Date:* 2005 to present day |  |

**Table 1 – Upper GI Cancer Search Criteria**

A systematic search was carried out by Healthcare Improvement Scotland using selected websites and two primary medical databases to identify national and international guidelines.

Of 39 relevant documents identified, 21 were excluded on the grounds that they were duplicate publications, not guidelines or had inadequate methodological information. The 18 remaining guidelines were appraised for quality using the AGREE21 II instrument. The instrument assesses the methodological rigour and precision used when developing a guideline. Sixteen of the guidelines were recommended for use.

***Indicator Development***

The Upper GI Cancer QPI Development Group defined evidence based, measurable indicators with a clear focus on improving the quality and outcome of care provided.

The group developed QPIs using the clinical recommendations set out in the briefing paper as a base, ensuring all indicators met the following criteria:

* **Overall importance** – does the indicator address an area of clinical importance that would significantly impact on the quality and outcome of care delivered?
* **Evidence base** – is the indicator based on high quality clinical evidence?
* **Measurability** – is the indicator measurable i.e. are there explicit requirements for data measurement and are the required data items accessible and available for collection?

***Engagement Process***

A wide clinical and public engagement exercise was undertaken as part of development in 2012 where the Upper GI Cancer QPIs, along with the accompanying draft minimum core dataset and measurability specifications, were made available of the Scottish Government website.

During the engagement period clinical and management colleagues were across NHSScotland, patients affected by upper GI cancer and the wider public were given the opportunity to influence the development of Upper GI Cancer QPIs.

Following the engagement period all comments and responses received were reviewed by the Upper GI Cancer QPI Development Group and used to produce and refine the final indicators.

***Upper GI Cancer QPI Development Group Membership (2012)***

| **Name** | **Designation** | **Cancer Network/Base** |
| --- | --- | --- |
| Jennifer Armstrong | Senior Medical Officer (CHAIR) | Scottish Government |
| Dougal Adamson | Consultant Oncologist | NOSCAN (Ninewells Hospital) |
| Alison Allen | Cancer Audit Manager | SCAN |
| Stuart Ballantyne | Consultant Radiologist | WoSCAN (Gartnavel General Hospital) |
| Sivanathan Chandramohan | Consultant Radiologist | WoSCAN (Gartnavel General Hospital) |
| Ron Coggins | Consultant Surgeon | NOSCAN (Raigmore Hospital) |
| Graeme Couper | Consultant Surgeon | SCAN (Edinburgh Royal Infirmary) |
| Jeff Evans | Consultant Oncologist | WoSCAN (Beatson West of Scotland Cancer Centre) |
| LJ Fon | Consultant Surgeon | WoSCAN (Crosshouse Hospital) |
| Matthew Forshaw | Consultant Surgeon | WoSCAN (Glasgow Royal Infirmary) |
| James Going | Consultant Pathologist | WoSCAN (Glasgow Royal Infirmary) |
| Louise Graham | Cancer Nurse Specialist | SCAN (Edinburgh Royal Infirmary) |
| Michele Hilton Boon | Programme Manager | Healthcare Improvement Scotland |
| Natasha Inglis | Consultant Pathologist | NOSCAN (Raigmore Hospital) |
| Rosie Kitching | Cancer Nurse Specialist | NOSCAN (Aberdeen Royal Infirmary) |
| Colin K MacKay | Consultant Surgeon | WoSCAN (Glasgow Royal Infirmary) |
| Mairi Macpherson | Cancer Nurse Specialist | WoSCAN (Forth Valley Royal Hospital) |
| Carol Marshall | Information Manager | WoSCAN |
| Dympna McAteer | Consultant Radiologist | NOSCAN (Aberdeen Royal Infirmary) |
| Susan McFadyen | Clinical Service Manager | WoSCAN (Glasgow Royal Infirmary) |
| Neil McLachlan | MCN Manager | NOSCAN |
| Brian Murray | Principal Information Development Manager | Information Services Division |
| David Oxenham | Medical Director | Marie Curie Hospice, Edinburgh |
| Russell Petty | Consultant Oncologist | NOSCAN (Aberdeen Royal Infirmary) |
| Perminder Phull | Consultant Gastroenterologist | NOSCAN (Aberdeen Royal Infirmary) |
| Lindsay Potts | Consultant Gastroenterologist | NOSCAN (Raigmore Hospital) |
| Caragh Rennie | Cancer Audit Facilitator | WoSCAN (Glasgow Royal Infirmary) |
| Vicki Save | Consultant Pathologist | SCAN (Edinburgh Royal Infirmary) |
| Iona Scott | Project Manager | WoSCAN |
| Sami Shimi | Consultant Surgeon | NOSCAN (Ninewells Hospital) |
| Evelyn Thomson | Regional Manager (Cancer) | WoSCAN |

NOSCAN – North of Scotland Cancer Network

SCAN – South East Scotland Cancer Network

WoSCAN – West of Scotland Cancer Network

## Appendix 2: Upper GI Cancer QPI Formal Reviews

Formal review of the Upper GI Cancer QPIs was undertaken for the first time in September 2016 following reporting of 3 years of national QPI data. A Formal Review Group was convened, chaired by Professor Alan McNeill, Consultant Urologist, Western General Hospital, Edinburgh. Membership of this group is outlined below.

***Upper GI Cancer QPI Formal Review Group Membership (2016)***

|  |  |  |
| --- | --- | --- |
| **Name** | **Designation** | **Cancer Network** |
| Alan McNeill | Consultant Urologist (CHAIR) | SCAN |
| Stuart Oglesby | Clinical Lead, Upper GI Cancer MCN | NOSCAN |
| Peter Lamb | Clinical Lead, Upper GI Cancer MCN | SCAN |
| Matthew Forshaw | Clinical Lead, Upper GI Cancer MCN | WoSCAN |
| Richard Skipworth | Consultant in General and Upper GI Surgery | SCAN |
| Evelyn Thomson | Regional Manager (Cancer) | WoSCAN |
| Christine Urquhart | Audit Manager | NOSCAN |
| Jen Doherty | Project Co-ordinator | National Cancer Quality Programme |

Formal review of the Upper GI Cancer QPIs has been undertaken in consultation with various other clinical specialties e.g. Oncology and Pathology

NOSCAN – North of Scotland Cancer Network

SCAN – South East Scotland Cancer Network

WoSCAN – West of Scotland Cancer Network

***2nd Cycle Formal Review***

The 2nd Cycle of Formal Review commenced in September 2019. This cycle was more selective and focussed on ensuring the ongoing clinical relevance of the QPIs. A Formal Review Group was convened, with Professor Rob Jones, Professor of Clinical Cancer Research and Honorary Consultant in Medical Oncology appointed as Clinical Advisor/Chair to the group. Membership of this groups is outlined below.

***Upper GI Cancer QPI Formal Review Group Membership (2019)***

|  |  |  |
| --- | --- | --- |
| **Name** | **Designation** | **Cancer Network** |
| Rob Jones | Consultant Medical Oncologist (Chair) | WoSCAN |
| Lorraine Cowie | Regional Manager (Cancer) | NCA |
| Jen Doherty | Project Co-ordinator | National Cancer Quality Programme |
| Peter Lamb | Clinical Lead, Upper GI Cancer MCN | SCAN |
| Andrew MacDonald | Clinical Lead, Upper GI Cancer MCN | WoSCAN |
| **Name** | **Designation** | **Cancer Network** |
| Russell Petty | Clinical Lead, Upper GI Cancer MCN | NCA |
| Richard Skipworth | Consultant in Upper GI Surgery | SCAN |
| Lorraine Stirling | Project Officer | National Cancer Quality Programme |
| Christine Urquhart | Audit Manager | NCA |

Formal review of the Upper GI Cancer QPIs has been undertaken in consultation with various other clinical specialties e.g. Oncology and Pathology

***3rd Cycle Formal Review***

The 3rd cycle of formal review commenced in September 2022. Mr Steve Leung, Consultant Urological Surgeon, SCAN was appointed as Clinical Advisor/Chair to the group. Membership of this group is outlined below:

***Upper GI Cancer QPI Formal Review Group Membership (2022)***

|  |  |  |
| --- | --- | --- |
| **Name** | **Designation** | **Cancer Network** |
| Steve Leung (Chair) | Consultant Urological Surgeon | SCAN |
| Jen Doherty | National Cancer Quality Programme Co-ordinator | National |
| Peter Lamb | Upper GI Caner Clinical Lead | SCAN |
| Andrew Macdonald | Upper GI Cancer Clinical Lead | WoSCAN |
| Bryan McKellar | Regional Manager (Cancer) | NCA |
| Shayanthan Nanthakumaran | Consultant Upper GI Surgeon | NCA |
| Stuart Oglesby | Consultant Upper GI Surgeon | NCA |
| Gillian Petty | MCN Manager | WoSCAN |
| Richard Skipworth | Consultant Upper GI Surgeon | SCAN |
| Lorraine Stirling | Project Officer, National Cancer Quality Programme | National |
| Christine Urquhart | Information Analyst | WoSCAN |

Formal review of the Upper GI Cancer QPIs has been undertaken in consultation with various other clinical specialties e.g. Oncology and Pathology

Appendix 3: 3 Yearly National Governance Process and Improvement Framework for Cancer Care

*This process is underpinned by the annual regional reporting and governance framework (see appendix 4).*

|  |  |
| --- | --- |
| **Development of nationally agreed QPIs, dataset and measurability** | **1. National QPI Development Stage**   * QPIs developed by QPI development groups, which include representation from Regional Cancer Networks, Healthcare Improvement Scotland, PHS, patient representatives and the Cancer Coalition. |
| **Data collection, analysis, reporting and publication**  ***Satisfactory performance*** | **2. Data Analysis Stage:**   * NHS Boards and Regional Cancer Advisory Groups (RCAGs)\* collect data and analyse on yearly basis using nationally agreed measurability criteria and produce action plans to address areas of variance, see appendix 4. * Submit yearly reports to PHS for collation and publication every 3 years. * National comparative report approved by NHS Boards and RCAGs. * PHS produce comparative, publicly available, national report consisting of trend analysis of 3 years data and survival analysis. |
| **Expert Review Group convened to review results**  **Where required, if significant variance identified** | **3. Expert Review Group Stage (for 3 tumour types per year):**   * Expert group, hosted by Healthcare Improvement Scotland, review comparative national results. * Write to RCAGs highlighting areas of good practice and variances. * Where required NHS Boards requested to submit improvement plans for any outstanding unresolved issues with timescales for improvement to expert group. * Improvement plans ratified by expert group and National Cancer Recovery Group. |
| **Improvement Support** | **4. Improvement Support Stage:**   * Where required Healthcare Improvement Scotland provide expertise on improvement methodologies and support. |
| **If progress acceptable**  **Monitoring**  **If progress not acceptable** | **5. Monitoring Stage:**   * RCAGs work with Boards to progress outstanding actions, monitor improvement plans and submit progress report to National Cancer Recovery Group. * Healthcare Improvement Scotland report to Scottish Cancer Taskforce as to whether progress is acceptable**.** |
| **Action if failure to progress improvement** | **6. Escalation Stage:**   * If progress not acceptable, Healthcare Improvement Scotland will visit the service concerned and work with the RCAG and Board to address issues. * Report submitted to National Cancer Recovery Group and escalation with a proposal to take forward to Scottish Government Health Department. |

\*The Regional Cancer Planning Group (South and East of Scotland) and the North Cancer Clinical Leadership Group (North Cancer Alliance) are equivalent to the Regional Cancer Advisory Group (RCAG) in the West of Scotland.

## Appendix 4: Regional Annual Governance Process and Improvement Framework for Cancer Care

|  |  |
| --- | --- |
| **Regional implementation of nationally agreed QPIs** | **1. Regional QPI Implementation Stage:**   * National cancer QPIs and associated national minimum core dataset and measurability specifications, developed by QPI development groups. * Regional implementation of nationally agreed dataset to enable reporting of QPIs. |
| **Data collection, analysis, reporting and publication**  **Satisfactory performance** | **2. Data Analysis Stage:**   * NHS Boards collect data and data is analysed on a yearly basis using nationally agreed measurability criteria at local/ regional level. * Data/results validated by Boards and annual regional comparative report produced by Regional Networks. * Areas of best practice and variance across the region highlighted. * Yearly regional reports submitted to PHS for collation and presentation in national report every 3 years. |
| **Results reviewed by RCAGs** | **3. Regional Performance Review Stage:**   * RCAGs\* review regional comparative report. * Regional or local NHS Board action plans to address areas of variance developed. * Appropriate leads identified to progress each action. * Action plans ratified by RCAGs. |
| **Monitoring** | **4. Monitoring Stage:**   * Where required, NHS Boards monitor progress with action plans and submit progress reports to RCAGs. * RCAGs review and monitor regional improvement. |
| **If progress acceptable**  **Improvement Support**  **If progress not acceptable** | **5. Improvement Support Stage:**   * Where required Healthcare Improvement Scotland maybe requested to provide expertise to NHS Boards/RCAGs on improvement methodologies and support. |
| **Action if failure to progress improvement** | **6. Escalation Stage:**   * If progress not acceptable, RCAGs will escalate any issues to relevant Board Chief Executives. If progress remains unacceptable RCAGs will escalate any relevant issues to Healthcare Improvement Scotland. |

\*The Regional Cancer Planning Group (South and East of Scotland) and the North Cancer Clinical Leadership Group (North Cancer Alliance) are equivalent to the Regional Cancer Advisory Group (RCAG) in the West of Scotland.

## Appendix 5: Glossary of Terms

|  |  |
| --- | --- |
| **Ablative therapy** | See *Cryotherapy* and *Radiofrequency Ablation* |
| **Active treatment** | Treatment which is intended to improve the cancer and/or alleviate symptoms, as opposed to supportive care. |
| **Adjuvant therapy / treatment** | Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. |
| **Biopsy** | Removal of a sample of tissue from the body to assist in diagnosis of a disease. |
| **Chemoradiotherapy** | Treatment that combines chemotherapy with radiotherapy. |
| **Chemotherapy** | The use of drugs that kill cancer cells, or prevent or slow their growth. |
| **Circumferential resection margins** | Margins of tissue surrounding a cancer after it has been removed. |
| **Clinical trials** | A type of research study that tests how well new medical approaches or medicines work. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease. |
| **Co-morbidity** | The condition of having two or more diseases at the same time. |
| **Computed Tomography (CT)** | An x-ray imaging technique, which allows detailed investigation of the internal organ of the body. |
| **Contra-indications** | A symptom or medical condition that makes a particular treatment or procedure inadvisable because a person is likely to have a bad reaction. |
| **Cryotherapy** | A treatment which aims to eradicate cancer by freezing. |
| **Curative treatment** | Treatment which is given with the aim of curing the cancer. |
| **Diagnosis** | The process of identifying a disease, such as cancer, from its signs and symptoms. |
| **Dietetic** | The application of the principles of nutrition to the selection of food and feeding. |
| **Dissection** | Cutting apart and separation of body tissues and organs in the course of an operation. |
| **Endoscopy** | A procedure that uses an endoscope to examine the inside of the body. An endoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a tool to remove tissue to be checked under a microscope for signs of disease. |
| **External Beam Radiotherapy (EBRT)** | Treatment by radiation emitted from a source located at a distance from the body. |
| **Gastric** | Having to do with the stomach. |
| **Gastric distension** | A condition in which air fills the stomach. |
| **Human Epidermal growth factor Receptor (HER) 2** | One of many receptors on the surface of certain cells which can protect the cell from damage or stimulate it to grow. Herceptin (trastuzumab) can be used to treat HER2 positive tumours. |
| **High grade dysplasia** | Represents a more advanced progression towards  malignant transformation. |
| **Histological/ Histopathological** | The study of the structure, composition and function of tissues under the microscope, and their abnormalities. |
| **Intravenous contrast (IV)** | A substance administered directly into bloodstream to enhance the visibility of structures on imaging. |
| **Invasive** | Cancer that can or has spread from its histological original site. |
| **Lesion** | Tumour, mass, or other abnormality. |
| **Longitudinal** | Pertaining to a measurement in the direction of the long axis of an object, body, or organ |
| **Lymph nodes** | Small bean shaped organs located along the lymphatic system. Nodes filter bacteria or cancer cells that might travel through the lymphatic system. |
| **Lymphadenectomy** | A surgical procedure in which the lymph nodes are removed and a sample of tissue is checked under a microscope for signs of cancer. |
| **Malignant** | Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body |
| **Malnutrition** | A condition that occurs from having an unbalanced diet in which certain nutrients are lacking. |
| **Metastatic disease** | Spread of cancer away from the primary site to somewhere else, e.g. via the bloodstream or the lymphatic system. |
| **Mortality** | Either (1) the condition of being subject to death; or (2) the death rate, which reflects the number of deaths per unit of population in any specific region, age group, disease or other classification, usually expressed as deaths per 1000, 10,000 or 100,000. |
| **Multi-disciplinary team meeting (MDT)** | A meeting which is held on a regular basis, which is made up of participants from various disciplines appropriate to the disease area, where diagnosis, management, and appropriate treatment of patients is discussed and decided. |
| **Neo-adjuvant chemotherapy** | Drug treatment which is given before the treatment of a primary tumour with the aim of improving the results of surgery and preventing the development of metastases. |
| **Oesophagogastric** | Pertaining to the oesophagus and the stomach. |
| **Oesophagus/ Oesophageal** | The muscular membranous tube for the passage of food from the throat to the stomach; the gullet. |
| **Palliative** | Anything which serves to alleviate symptoms due to the underlying cancer but is not expected to cure it. |
| **Pathological** | The study of disease processes with the aim of understanding their nature and causes. This is achieved by observing samples of fluid and tissues obtained from the living patient by various methods, or at post mortem. |
| **Pathologist** | A doctor who identifies diseases by studying cells and tissues under a microscope. |
| **Program Death-Ligand 1 (PD-L1)** | A protein which prevents immune cells from attacking harmful cells in the body. Pembrolizumab can be used to treat tumours with PD-L1 expression. |
| **Peer review** | The process by which original articles and grants written by researchers are evaluated for technical and scientific quality and correctness by other experts in the same field. |
| **Positive surgical margin** | Margins of tissue that still have cancer cells present following surgery. |
| **Primary tumour** | The original tumour. |

|  |  |
| --- | --- |
| **Prognosis** | The likely outcome or course of a disease; the chance of recovery or recurrence. |
| **Prognostic Indicator** | Factors, such as staging, tumour type, and laboratory studies that may indicate treatment effectiveness and outcomes. |
| **Progression** | In medicine, the course of a disease, such as cancer, as it becomes worse or spreads in the body. |
| **Quality of life** | The overall enjoyment of life. Many clinical trials assess the effects of cancer and its treatment on the quality of life. These studies measure aspects of an individual’s sense of well-being and ability to carry out various activities. |
| **R0 resection** | A surgical procedure where the surgical margins are negative for cancer. |
| **Radical treatment** | Treatment that aims to get to completely get rid of a cancer. |
| **Resectable** | Able to be removed (resected) by surgery |
| **Resection Margin** | The rim of normal tissue surrounding a cancer after removal. These can be distal, proximal, or radial. |
| **Risk factor** | Something that is known to increase your chances of getting a disease. |
| **Screening** | Tests carried out in people without symptoms to detect cancer. |
| **Staging** | Process of describing to what degree cancer has spread from its original site to another part of the body. Staging involves clinical, surgical and pathology assessments. |
| **Stent insertion** | A slender/thin rod that is inserted into a tubular structure within the body to provide support to that structure. |
| **Surgical resection** | Surgical removal of the tumour/lesion. |
| **TNM staging system** | TNM classification is a system for staging the extent of cancer. T describes the size and penetration of the local tissues of the tumour. N refers to the involvement of the lymph nodes. M refers to the presence of metastatic disease. |
| **Treatment intent** | The reason for which treatment is given, that is, whether the treatment is intended to cure the disease or to alleviate symptoms. |

1. Patients may undergo endoscopies which are not related to their cancer diagnosis therefore within the measurement of this QPI the ‘initial endoscopy and biopsy’ will be identified if no endoscopy occurred within the previous year. [↑](#footnote-ref-1)
2. TNM classification is a system for staging the extent of cancer. T describes the size of the tumour. N refers to the involvement of the lymph nodes. M refers to the presence of metastatic disease. [↑](#footnote-ref-2)
3. Patients presenting with stage TxNxM1 disease have metastatic cancer where the extent of primary tumour or lymph node involvement cannot be assessed. [↑](#footnote-ref-3)